Expression of immune check point gene TIM‑3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome

Kamal,Amany M.; Nabih,Nermeen A.; Elleboudy,Nooran S.; Radwan,Sara M.

doi:10.3892/ol.2021.12587

Expression of immune check point gene TIM‑3 in patients newly diagnosed with acute myeloid leukemia: Significance and impact on outcome

Authors:
- Amany M. Kamal
- Nermeen A. Nabih
- Nooran S. Elleboudy
- Sara M. Radwan
View Affiliations

Affiliations: Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt, Department of Internal Medicine, Clinical Hematology and Bone Marrow Transplantation Unit, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt, Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt
Published online on: February 24, 2021 https://doi.org/10.3892/ol.2021.12587
Article Number: 325
Copyright: © Kamal et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite recent advancements in the therapeutic landscape of acute myeloid leukemia (AML), the prognosis of patients remains poor. Immune check point inhibitors have been investigated in hematological malignancies, including AML; however, the role of T‑cell immunoglobulin and mucin domain 3 (TIM‑3) in AML has not yet been fully elucidated. Thus, the present study aimed to investigate TIM‑3 gene expression in patients with AML and determine its associations with prognostic variables and clinical outcome. A total of 60 patients newly diagnosed with AML and 15 healthy matching individuals were recruited in the present study, and reverse transcription‑quantitative PCR analysis was performed to detect TIM‑3 expression. The results demonstrated that TIM‑3 expression was significantly upregulated in patients with AML compared with that in healthy individuals (P<0.001). In addition, patients with extramedullary disease (EMD) exhibited significantly lower median TIM‑3 expression levels compared with those without EMD (P=0.001). Furthermore, patients with high TIM‑3 expression had significantly lower complete remission rates following induction chemotherapy compared with those with low TIM‑3 expression (P=0.004). High TIM‑3 expression was significantly associated with lower overall survival rates during the 1‑year follow‑up (P=0.001). Taken together, the results of the present study suggest that TIM‑3 may act as a biomarker of a poor prognosis in patients with AML, and be used as a therapeutic target.

View Figures

View References

1	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–47. 2017. View Article : Google Scholar : PubMed/NCBI
2	Shallis RM, Wang R, Davidoff A, Ma X and Zeidan AM: Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 36:70–87. 2019. View Article : Google Scholar : PubMed/NCBI
3	Mohammadiasl J, Khosravi A, Shahjahani M, Azizidoost S and Saki N: Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia. J Cancer Metastasis Treat. 2:44–50. 2016.
4	Wang ES: Treating acute myeloid leukemia in older adults. Hematol Am Soc Hematol Educ Program. 2014:14–20. 2014. View Article : Google Scholar
5	Stahl M, Lu BY, Kim TK and Zeidan AM: Novel therapies for acute myeloid leukemia: Are we finally breaking the deadlock? Target Oncol. 12:413–447. 2017. View Article : Google Scholar : PubMed/NCBI
6	Lamble AJ and Lind EF: Targeting the immune microenvironment in acute myeloid leukemia: A focus on t cell immunity. Front Oncol. 8:2132018. View Article : Google Scholar : PubMed/NCBI
7	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
8	Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer M, Gostick E, Katsikis PD, Douek DC, et al: Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8⁺ T-cell exhaustion in HIV infection. Blood. 117:4805–4815. 2011. View Article : Google Scholar : PubMed/NCBI
9	Anderson AC, Joller N and Kuchroo VK: Lag-3, TIM-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 44:989–1004. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The TIM-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
11	Anderson AC: Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 24:213–216. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y and Akashi K: TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 7:708–7017. 2010. View Article : Google Scholar : PubMed/NCBI
13	Li C, Chen X, Yu X, Zhu Y, Ma C, Xia R, Ma J, Gu C, Ye L and Wu D: TIM-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Int J Clin Exp Pathol. 7:6880–6888. 2014.PubMed/NCBI
14	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI
15	Nunez R: Flow cytometry: Principles and instrumentation. Curr Issues Mol Biol. 3:39–45. 2001.PubMed/NCBI
16	Fröhling S, Skelin S, Liebisch C, Scholl C, Schlenk RF, Döhner H and Döhner K; Acute Myeloid Leukemia Study Group, Ulm, : Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. J Clin Oncol. 20:2480–2485. 2002. View Article : Google Scholar : PubMed/NCBI
17	O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, et al: NCCN clinical practice guidelines acute myeloid leukemia. J Natl Compr Canc Netw. 10:984–1021. 2012. View Article : Google Scholar : PubMed/NCBI
18	National Comprehensive Cancer Network: Acute myeloid leukemia (Version 2. 2018). http://www.nccn.org/professionals/physician_gls/pdf/aml
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Wians FH: Clinical laboratory tests: Which, why, and what do the results mean? Laboratory Med. 40:105–113. 2009. View Article : Google Scholar
21	Song X, Peng Y, Wang X, Chen Y, Jin L, Yang T, Qian M, Ni W, Tong X and Lan J: Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: Analysis of the surveillance, epidemiology, and end results (SEER) database, 2001–2013. Acta Haematol. 139:115–127. 2018. View Article : Google Scholar : PubMed/NCBI
22	Prokocimer M, Molchadsky A and Rotter V: Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: Projections on diagnostic work up and therapy. Blood. 130:699–712. 2017. View Article : Google Scholar : PubMed/NCBI
23	Radwan SM, Elleboudy NS, Nabih NA and Kamal AM: The immune checkpoints cytotoxic T Lymphocyte Antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia. HLA. 96:3–12. 2020. View Article : Google Scholar : PubMed/NCBI
24	Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC: Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
25	Darwish NHE, Sudha T, Godugu K, Elbaz O, Abdelghaffar HA, Hassan EE and Mousa SA: Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: Potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 7:57811–57820. 2016. View Article : Google Scholar : PubMed/NCBI
26	Xu L, Xu J, Ma S, Li X, Zhu M, Chen S, Han Y, Tang X, Fu Z, Qiu H, et al: High TIM-3 expression chemotherapy sensitivity on AML blasts could enhance chemotherapy sensitivity. Oncotarget. 8:102088–102096. 2017. View Article : Google Scholar : PubMed/NCBI
27	Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL and Majeti R: Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA. 108:5009–5014. 2011. View Article : Google Scholar : PubMed/NCBI
28	Tan J, Huang S, Huang J, Yu Z, Chen Y, Lu Y, Li Y and Chen S: Increasing Tim-3⁺CD244⁺, Tim-3⁺CD57⁺, and Tim-3⁺PD-1⁺ T cells in patients with acute myeloid leukemia. Asia Pac J Clin Oncol. 16:137–141. 2020. View Article : Google Scholar : PubMed/NCBI
29	Silva IG, Gibbs BF, Bardelli M, Varani L and Sumbayev VV: Differential expression and biochemical activity of the immune receptor TIM-3 in healthy and malignant human myeloid cells. Oncotarget. 6:33823–33833. 2015. View Article : Google Scholar : PubMed/NCBI
30	Radwan SM, Hamdy NM, Hegab HM and El-Mesallamy HO: Beclin-1 and hypoxia-inducible factor-1α genes expression: Potential biomarkers in acute leukemia patients. Cancer Biomark. 16:619–26. 2016. View Article : Google Scholar : PubMed/NCBI
31	Sinha K: Prognostic significance of flowcytometric immunophenotype in acute leukemias: Insights gained at a tertiary care hospital. J Dental Med Sci. 18:55–58. 2019.
32	Jiang L, Yu G, Meng W, Wang Z, Meng F and Ma W: Overexpression of amyloid precursor protein in acute myeloid leukemia enhances extramedullary infiltration by MMP-2. Tumor Biol. 34:629–636. 2013. View Article : Google Scholar
33	Kikushige Y and Miyamoto T: TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 98:627–633. 2013. View Article : Google Scholar : PubMed/NCBI